FDA spurns Supernus for Parkinson's drug, noting application issues 'across several areas'
Supernus has found itself in the crosshairs of the FDA once again.
A pitch for a Parkinson’s disease treatment was rejected by regulators, the biotech …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
